coin-img-OWLOWL-2.95%coin-img-FOGOFOGO-13.40%coin-img-SPORTFUNSPORTFUN-6.16%coin-img-XUEQIUXUEQIU+14.31%coin-img-ETHETH+0.41%coin-img-BTCBTC-0.40%coin-img-SOLSOL-1.37%coin-img-XRPXRP-0.36%coin-img-OWLOWL-2.95%coin-img-FOGOFOGO-13.40%coin-img-SPORTFUNSPORTFUN-6.16%coin-img-XUEQIUXUEQIU+14.31%coin-img-ETHETH+0.41%coin-img-BTCBTC-0.40%coin-img-SOLSOL-1.37%coin-img-XRPXRP-0.36%coin-img-OWLOWL-2.95%coin-img-FOGOFOGO-13.40%coin-img-SPORTFUNSPORTFUN-6.16%coin-img-XUEQIUXUEQIU+14.31%coin-img-ETHETH+0.41%coin-img-BTCBTC-0.40%coin-img-SOLSOL-1.37%coin-img-XRPXRP-0.36%coin-img-OWLOWL-2.95%coin-img-FOGOFOGO-13.40%coin-img-SPORTFUNSPORTFUN-6.16%coin-img-XUEQIUXUEQIU+14.31%coin-img-ETHETH+0.41%coin-img-BTCBTC-0.40%coin-img-SOLSOL-1.37%coin-img-XRPXRP-0.36%
user-avatar
Tim Fries

Ocular Therapeutix Jumps 18% Premarket After Turning Down Sanofi's $16-per-Share Takeover Offer

On January 15, 2026, Ocular Therapeutix stock climbed about 18% in premarket trading to $13.11 after the company rejected a $16 per share acquisition proposal from Sanofi. The move, backed by a strong cash position and a late-stage pipeline led by AXPAXLI (OTX-TKI), has reinforced investor expectations for upcoming Phase 3 trial readouts in wet age-related macular degeneration.
Disclaimer: The content above is only the author's opinion and does not represent BingX’s stance. It shall not be construed as investment advice from BingX. For details, refer to the Terms and Conditions.